We have successfully developed a canine cancer gene panel that we have called the Canine Oncopanel, using cutting-edge, next-generation sequencing technology (NGS). The Canine Oncopanel allows sequencing of 283 cancer-related genes and detection of mutations within these genes that may drive the tumor cells to proliferate and survive. The canine oncopanel sequences a total target region that equates to ~3% of the canine genome. Analyzing the genomic composition of this broad target region allows evaluation of common genomic alterations that can lead to the development of cancer. The Canine Oncopanel is suitable to map mutation profiles and identify driver mechanisms in both common and rare canine cancers to provide a better understanding of the tumor genome and its biology.
RESULTS: New Technology Helps Detect Small Amounts of Drug-Resistant Cancer Cells in Dogs with T-cell Lymphoma.
Morris Animal Foundation-funded researchers from North Carolina State University used state-of-the-art DNA technology to help detect small amounts of drug-resistant cancer cells that persist after treatment in dogs with T-cell lymphoma (minimal residual disease, MRD). Accurately monitoring MRD could provide a fuller picture of the effectiveness of different drugs and improve treatment success, quality of life and survival for these patients. Continue reading “Research Update MAF D16CA-056 Final: Measuring Chemotherapy Drug Resistance in Dogs with T-cell Lymphoma”
This study involved the evaluation of canine lymphoma biopsy specimens for the presence of tumor-associated abnormalities associated with four key cancer-associated genes (MYC, BCL6, BCL2, and TP53). In a subset of human lymphoma patients, cancer cells show structural rearrangements of MYC, BCL2, and/or BCL6, meaning that the normal organization of the gene has become disrupted in the tumor. Human lymphomas also frequently show DNA sequence mutations in the TP53 tumor suppressor gene. The presence of these abnormalities, alone and particular in combination, has been shown to be predictive of a poor response to standard treatment modalities in human lymphoma patients, and provides powerful opportunities to predict prognosis in newly diagnosed patients. Continue reading “Research Update CHF 02317 Final: The Role of Complex Translocations Associated with TP53 Somatic Mutations for Aiding Prognosis of Canine Diffuse Large B-Cell Lymphoma”
The clinical response of dogs with lymphoma to multi-agent chemotherapy is highly variable. Although up to 85% of dogs respond initially, some relapse within weeks, while others enjoy remission times of two years. This heterogeneity in clinical response is in part explained by the recognition that “lymphoma” is not a single disease entity but consists of different subtypes that can be characterized on a molecular level by mutations in specific genes. Continue reading “Research Update CHF 02502 MY3: Precision Medicine for Canine Lymphoma”
Lymphoma, particularly the large, B-cell subtype, is one of the most common malignancies in dogs. Canine lymphoma can be treated, but it is rarely cured. Novel therapeutic strategies are necessary to improve outcomes in dogs diagnosed with lymphoma. Recently, advances in the understanding of human lymphomas have focused on the area of epigenetics.
This AKC-CHF sponsored award supported the successful development of a comprehensive canine tumor sequencing panel (“canine oncopanel”) using cutting-edge, next-generation sequencing technology.
Update on treatment of B-cell lymphoma from Dr Breen.
Continue reading “Research Update CHF Grant 02317 Update End-Year 3: The Role of Complex Translocations Associated with TP53 Somatic Mutations for Aiding Prognosis of Canine Diffuse Large B-Cell Lymphoma”
Update on targeting epigenome for treatment of B-cell lymphoma from Dr McCleary-Wheeler.
Research update from Dr. Nicola Mason to profile lymphoma and enable targeted therapy.
Final Research Update from Dr. Trepanier on genetic and environmental risks of lymphoma in Boxer dogs.